



Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	10/640,989
Filing Date	August 14, 2003
First Named Inventor	YANG
Art Unit	1651
Examiner Name	
Attorney Docket Number	5853-261

Publication Date	Name
------------------	------

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
leb		WO 00/50048-A2	08/31/2000	UNIVERSITY OF PITTSBURGH		


Examiner Signature		Date Considered	8/3/05
-----------------------	---	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

***If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.***



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/640,989
		Filing Date	August 14, 2003
		First Named Inventor	YANG
		Art Unit	1651
Examiner Name			
Sheet 1 of 3	Attorney Docket Number	5853-261	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
leb		BUSCHARD et al., "Neonatal treatment with beta-cell stimulatory agents reduces the incidence of diabetes in BB rats," Int. J. Exp. Diabetes Res. 1:1-8, 2000.	
		HOHMEIER et al., "ISOLATION OF INS-1-DERIVED CELL LINES WITH ROBUST ATP-SENSITIVE K <sup>+</sup> CHANNEL-DEPENDENT AND-INDEPENDENT GLUCOSE-STIMULATED INSULIN SECRETION," Diabetes 49: 424-430, 2000.	
		SHAPIRO et al., "Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen," N. Engl. J. Med. 343:230-238, 2000.	
		YANG et al., "In Vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells.," PNAS 99:8078-8083, 2002.	
		DEUTSCH et al., "A bipotential precursor population for pancreas and liver within the embryonic endoderm," Development 128:871-881, 2001.	
		REYES et al., "Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells," Blood 98:2615-2625, 2001.	
		BONNER-WEIR, "In vitro cultivation of human islets from expanded ductal tissue," PNAS 97:7999-8004, 2000.	
		RAMIYA et al., "Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells," Nat.Med. 6:278-282, 2000.	
		IANUS et al., "In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion," J.Clin.Invest 111:843-850, 2003.	
		RAJAGOPAL et al., "Insulin Staining of ES Cell Progeny from Insulin Uptake," Science 299:363, 2003.	

Examiner Signature		Date Considered	8/3/05
--------------------	--	-----------------	--------

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/640,989
Filing Date	August 14, 2003
First Named Inventor	YANG
Art Unit	1651
Examiner Name	
Attorney Docket Number	5853-261

Sheet

2

of

3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
leb		XU et al., "Exendin-4 Stimulates Both Beta-Cell Replication and Neogenesis, Resulting in Increased Beta-Cell Mass and Improved Glucose Tolerance in Diabetic Rats," Diabetes 48:2270-2276, 1999.	
		AKIYAMA et al., "Activation of Reg gene, a gene for insulin-producing beta-cell regeneration: Poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly (ADP-ribosyl)ation. PNAS 98:48-53, 2001.	
		KOJIMA et al., "NeuroD-beta-cellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice," Nature Medicine 9:596-603, 2003.	
		CORNELIUS et al., "In vitro-generation of islets in long-term cultures of pluripotent stem cells from adult mouse pancreas," Horm Metab. Res. 29: 271-277, 1997.	
		LUMELSKY et al., "Differentiation of Embryonic Stem Cells to Insulin-Secreting Structures Similar to Pancreatic Islets," Science 292:1389-1394, 2001.	
		ASSADY et al., "Insulin Production by Human Embryonic Stem Cells," Diabetes 50:1691-1697, 2001.	
		PETERSEN et al., "Bone Marrow as a Potential Source of Hepatic Oval Cells," Science 284:1168-1170, 1999.	
		OTONKOSKI et al., "Nicotinamide is a potent inducer of endocrine differentiation in cultured human fetal pancreatic cells," J. Clin. Invest, 92:1459-1466, 1993.	
		SORIA et al., "From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus," Diabetologia 44:407-415, 2001.	
		ZULEWSKI et al., "Multipotential Nestin-Positive Stem Cells Isolated From Adult Pancreatic Islets Differentiate Ex Vivo Into Pancreatic Endocrine, Exocrine, and Hepatic Phenotypes," Diabetes 50:521-533, 2001.	

Examiner Signature		Date Considered	8/3/05
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)


**Complete if Known**

Application Number	10/640,989
Filing Date	August 14, 2003
First Named Inventor	YANG
Art Unit	1651
Examiner Name	
Attorney Docket Number	5853-261

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
lev		SJOHOLM et al. "Role of polyamines in mitogenic and secretory responses of pancreatic beta-cells to growth factors," Am J. Physiol. 259:C828-C833, 1990.	
		VOGEL, "Same Results, Different Interpretations," Science 299:324, 2003.	
		HESS et al., "Bone-marrow-derived stem cells initiate pancreatic regeneration," Nature Biotechnology 21:763-770, 2003.	
		DENG et al., "Neural trans-differentiation potential of hepatic oval cells in the neonatal mouse brain," Experimental Neurology 182:373-382, 2003.	
		HELLERSTROM et al., "Functional Maturation and Proliferation of Fear Pancreatic B-Cells," Diabetes 40:89-93, 1991.	

Examiner Signature		Date Considered	8/3/05
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.